About Rui Ning
development process
2018
◦ Jan 2018: Reunion Biotech is officially founded
2019
◦ Introduced the world’s first ready-to-use PEG hydrogel technology
2020
◦ Dec 2020: Completed angel round funding
2021
◦ Jun 2021: Completed Pre-A round funding
◦ Nov 2021: Launched clinical trials for cervical cancer registration
◦ Dec 2021: Secured Series A funding
◦ Nov 2021: Launched clinical trials for cervical cancer registration
◦ Dec 2021: Secured Series A funding
2022
◦ Jun 2022: Received the “Development Potential Award” from Jiading Industrial Zone
◦ Sep 2022: Opened new headquarters and cleanroom facility in Jiading, Shanghai
◦ Sep 2022: Completed Series A+ funding
◦ Sep 2022: Opened new headquarters and cleanroom facility in Jiading, Shanghai
◦ Sep 2022: Completed Series A+ funding
2023
◦ Mar 2023: Honored with the title of “Specialized and Sophisticated Enterprise that Produces New and Unique Products” by the Shanghai Government
◦ Jun 2023: Concluded enrollment of all cases in the cervical cancer registration clinical project
◦ Jul 2023: Founder Pan Zhen named among Fortune China’s 40 Under 40 business elites
◦ Jun 2023: Concluded enrollment of all cases in the cervical cancer registration clinical project
◦ Jul 2023: Founder Pan Zhen named among Fortune China’s 40 Under 40 business elites
2024
◦ Jan 2024: Completed Series B funding
◦ Mar 2024: Enrolled the first patient in the exploratory clinical trial for liver cancer
◦ Aug 2024: Honored the first prize in the Medical Materials and Assistive Devices category at the 7th China Medical Device Innovation and Entrepreneurship Competition (2024)
◦ Mar 2024: Enrolled the first patient in the exploratory clinical trial for liver cancer
◦ Aug 2024: Honored the first prize in the Medical Materials and Assistive Devices category at the 7th China Medical Device Innovation and Entrepreneurship Competition (2024)
Milestones
development process
2018
◦ Jan 2018: Reunion Biotech is officially founded
2019
◦ Introduced the world’s first ready-to-use PEG hydrogel technology
2020
◦ Dec 2020: Completed angel round funding
2021
◦ Jun 2021: Completed Pre-A round funding
◦ Nov 2021: Launched clinical trials for cervical cancer registration
◦ Dec 2021: Secured Series A funding
◦ Nov 2021: Launched clinical trials for cervical cancer registration
◦ Dec 2021: Secured Series A funding
2022
◦ Jun 2022: Received the “Development Potential Award” from Jiading Industrial Zone
◦ Sep 2022: Opened new headquarters and cleanroom facility in Jiading, Shanghai
◦ Sep 2022: Completed Series A+ funding
◦ Sep 2022: Opened new headquarters and cleanroom facility in Jiading, Shanghai
◦ Sep 2022: Completed Series A+ funding
2023
◦ Mar 2023: Honored with the title of “Specialized and Sophisticated Enterprise that Produces New and Unique Products” by the Shanghai Government
◦ Jun 2023: Concluded enrollment of all cases in the cervical cancer registration clinical project
◦ Jul 2023: Founder Pan Zhen named among Fortune China’s 40 Under 40 business elites
◦ Jun 2023: Concluded enrollment of all cases in the cervical cancer registration clinical project
◦ Jul 2023: Founder Pan Zhen named among Fortune China’s 40 Under 40 business elites
2024
◦ Jan 2024: Completed Series B funding
◦ Mar 2024: Enrolled the first patient in the exploratory clinical trial for liver cancer
◦ Aug 2024: Honored the first prize in the Medical Materials and Assistive Devices category at the 7th China Medical Device Innovation and Entrepreneurship Competition (2024)
◦ Mar 2024: Enrolled the first patient in the exploratory clinical trial for liver cancer
◦ Aug 2024: Honored the first prize in the Medical Materials and Assistive Devices category at the 7th China Medical Device Innovation and Entrepreneurship Competition (2024)
Contact Us
Telephone: 021-51592768
E-mail: cs@reunionmed.com
Address: Floor 2, Building 7, 1630 Yecheng Road, Jiading District, Shanghai
Scan QR Code